Back

Interim 2023/24 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom

Whitaker, H.; Findlay, B.; Zitha, J.; Goudie, R.; Hassell, K.; Evans, J.; Kalapotharakou, P.; Agrawal, U.; Kele, B.; Hamilton, M.; Moore, C.; Byford, R.; Stowe, J.; Robertson, C.; Couzens, A.; Jamie, G.; Hoschler, K.; Pheasant, K.; Button, E.; Quinot, C.; Jones, T.; Anand, S.; Watson, C.; Andrews, N.; de Lusignan, S.; Zambon, M.; Williams, C.; Cottrell, S.; Marsh, K.; McMenamin, J.; Lopez-Bernal, J.

2024-02-28 infectious diseases
10.1101/2024.02.27.24303426 medRxiv
Show abstract

We report 2023/24 season interim influenza vaccine effectiveness for three studies, including primary care in Great Britain, hospital settings in Scotland and hospital settings in England. Adjusted vaccine effectiveness against all influenzas ranged from 63% (46 to 75%) to 65% (41 to 79%) among children aged 2-17, from 36% (20 to 49%) to 55% (43 to 65%) among adults 18-64 and from 40% (29 to 50%) to 55% (32 to 70%) among adults aged 65 and over.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.